Use of two mcf-7 cell variants to evaluate the growth regulatory potential of estrogen-induced products

Nancy E. Davidson, Diane A. Bronzert, Edward P. Gelmann, Marc E. Lippman, Pierre Chambon

Research output: Contribution to journalArticle

Abstract

Two variants of the human estrogen-responsive breast cancer cell line MCF-7, were utilized to study the expression of an estrogen-induced gene, pS2, and an estrogen-induced Mr52,000 protein. One variant cell line, 113, is growth inhibited after chronic exposure to estrogen. Both the pS2 gene product and the Mr 52,000 protein were produced at maximal levels at a time when 113 growth was inhibited by estrogen. The variant cell line, LY2, selected for its resistance to the growth-inhibitory effects of the antiestrogen, LY117018, grew normally in the presence of this drug, although both pS2 expression and Mr52,000 protein production were inhibited. These results confirm that the pS2 gene and Mr 52,000 protein are estrogen-regulated elements, but the lack of correlation between their activities and variant cell growth suggests that they are not major autocrine growth-stimulatory agents.

Original languageEnglish (US)
Pages (from-to)1904-1908
Number of pages5
JournalCancer Research
Volume46
StatePublished - Apr 1986

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Use of two mcf-7 cell variants to evaluate the growth regulatory potential of estrogen-induced products'. Together they form a unique fingerprint.

  • Cite this

    Davidson, N. E., Bronzert, D. A., Gelmann, E. P., Lippman, M. E., & Chambon, P. (1986). Use of two mcf-7 cell variants to evaluate the growth regulatory potential of estrogen-induced products. Cancer Research, 46, 1904-1908.